Similar Papers

Paper Title
Journal
Date
Author
Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Vinita Popat ... David E Gerber
The oncologist | VOL. 25
Vinita Popat, et. al.Vinita Popat ... David E Gerber
31 Mar 2020
A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer.
Aya El Helali ... Wing Fong Wu
Frontiers in Oncology | VOL. 12
Aya El Helali, et. al.Aya El Helali ... Wing Fong Wu
31 Oct 2022
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Vivek Kumar ... Osama E Rahma
The Oncologist | VOL. 25
Vivek Kumar, et. al.Vivek Kumar ... Osama E Rahma
11 Feb 2020
Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease.
Kinnosuke Matsumoto ... Takatoshi Enomoto
Respirology (Carlton, Vic.) | VOL. 25
Kinnosuke Matsumoto, et. al.Kinnosuke Matsumoto ... Takatoshi Enomoto
19 Feb 2020
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Comments on The Study of Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma
Yue-Can Zeng ... Yi Wang
Annals of Oncology | VOL. -
Yue-Can Zeng, et. al.Yue-Can Zeng ... Yi Wang
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.